Merck KGaA: 2 bln eur pipeline potential driven by cancer, MS drugs

FRANKFURT, June 12 (Reuters) - Germany's Merck KGaA said its forecast of 2 billion euros ($2.24 billion) in 2020 sales from drugs under development was above the analyst consensus mainly because of the underrated potential of cancer drug avelumab and multiple sclerosis treatment cladribine.

by reutersCOMPANYNEWS via Endless Supplies .Biz - News